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Abstract
Introduction The UK pharmacists with independent prescribing rights (pharmacist independent 
prescribers [PIPs]) are authorised to prescribe within their areas of competence. To enable PIPs to 
provide pharmaceutical care to residents in care homes and assume responsibility for medicines 
management, a process for development and assessment of competence is required. The aim of 
this research was to develop a training and accreditation process (training programme) to enable 
PIPs to operate safely and effectively within care homes.
Methods Located in England, Scotland and Northern Ireland across four sites and based on a sys-
tematic review, it consisted of four phases: (1) initial stakeholder engagement, (2) uni-professional 
focus groups and interviews, (3) expert panel consensus and (4) feasibility testing. Four PIPs were 
trained each to provide pharmaceutical care to 10 care home residents. An expert panel synthesised 
the evidence at each stage to develop each iteration of the training programme. Content analysis 
was used throughout.
Results Differences in baseline knowledge of PIPs required inclusion of a Personal Development 
Framework and the provision of a mentor. Face-to-face training focussed on managing medicines 
for a complex older person, minimising prescribing costs and supporting people without capacity. 
Provision of time to understand local context and develop relationships with care homes and 







niversity of Aberdeen user on 22 Septem
ber 2021
International Journal of Pharmacy Practice, 2021, Vol. 29, No. 4 377
via viva. Feasibility testing demonstrated that the derived training programme was acceptable, 
practical and effective.
Discussion The model seemed to work, but due to small numbers, larger-scale testing of the 
training programme is now required.
Keywords: care home; training; Personal Development Framework; pharmacist; prescriber
Introduction 
Care homes, with or without nursing support, provide personal and/
or nursing care for individuals who are no longer able to live in-
dependently in their own home. Whereas the proportion of people 
over the age of 65 living within care homes has either stabilised or 
reduced in Europe and North America, the number of residents 
continues to increase as populations age.[1] With a wide range and 
number of co-morbidities, medicines are a central element of resi-
dents’ care, with the average number of regular medicines/resident 
reported to be between 7 and 10.[2–4]
The prevalence of medicines-related errors in care homes is re-
ported to be high. One large observational study, in 2009, found 
that almost 70% of care home residents experienced at least one 
medication error on any given day.[2] A systematic review of inter-
ventions to improve medication use within care homes reported the 
most common medicines-related errors included unnecessary pro-
longation of therapy, drug–drug interactions, sub-therapeutic doses 
and inadequate monitoring of therapy.[5]
The most commonly reported intervention to improve pharma-
ceutical care within care homes is pharmacist-led medication re-
view.[5] The pharmacist role can also include care home staff 
training,[6] working in a multidisciplinary manner with the resident’s 
doctor[7] and assuming responsibility for all elements of medicines-
related care.[8] The current evidence base for such interventions sug-
gests that none of these models are optimal.[5, 9]
Although improvements in medication appropriateness have 
been demonstrated, the impact on clinical outcomes is mixed.[5, 9] 
One recent systematic review based on studies reporting secondary 
outcomes suggested that pharmacist interventions could potentially 
reduce falls,[10] with a more recent research review contradicting 
this,[7] and concluding that better models of care are required.
Legislative changes in the UK in 2006 enabled accredited phar-
macists to independently prescribe[11] and enabled pharmacists 
to assume responsibility for pharmaceutical care in care homes, 
implementing their own interventions without secondary author-
isation. Evidence is now emerging regarding the effectiveness of 
pharmacist prescribers in the provision of patient care.[12, 13]
Pharmacist independent prescribers (PIPs) in the UK are required 
to demonstrate competency against a national generic prescribing 
framework[14] and then practise only within their defined area of 
competence. Consequently, to be able to provide pharmaceutical 
care within the care home environment and prescribe for such resi-
dents, they would be expected to be competent to do so.
In 2012, the UK National Institute for Health Research (NIHR), 
funded a programme of work, the Care Home Independent 
Prescribing Pharmacist Study (CHIPPS), whereby pharmacists with 
prescribing rights were to be located within care homes and assume 
responsibility for providing pharmaceutical care. This was to be 
achieved largely through the development of pharmaceutical care 
plans and optimising prescribing through monthly authorisation of 
repeat medication, implementing prescription changes as needed, 
while also providing oversight for drug storage, ordering, manage-
ment and dispensing within the care home by their staff.[15]
The CHIPPS programme of research comprised six work pack-
ages one of which was to develop a training programme to support the 
enhancement of intervention fidelity within the trial and enable PIPs 
to operate within UK legislation. Early work identified the need for 
a formal accreditation process within this to reassure care homes and 
their associated medical practitioners of the safety of the proposal.[16]
Using Eraut’s definition of knowledge required for workplace 
learning,[17] we have previously reported a systematic review with 
narrative synthesis to identify the knowledge requirements for phar-
macists operating within the care home environment. This was cat-
egorised as codified knowledge (written down), practical knowledge 
(required to perform tasks) and cultural knowledge (how things are 
done around here).[18] We acknowledged that publication bias was 
likely to limit the capture of more mundane roles. Furthermore, due 
to the limited consideration of the specific training needs for phar-
macists to operate in care homes within the literature, we identified 
the need for further qualitative work with all stakeholders to obtain 
a more complete picture to inform our training programme.
The aim of the work package was therefore to develop, and feasi-
bility test a training programme to enable PIPs to provide pharma-
ceutical care safely and effectively within the care home environment.
Method
CHIPPS was located in Aberdeen (Scotland), Belfast (Northern 
Ireland), Leeds (Northern England) and Norwich (South East 
England) and consisted of four phases: (1) initial stakeholder en-
gagement, (2) uni-professional focus groups and interviews, (3) ex-
pert panel consensus and (4) feasibility testing.
An Expert Advisory Panel (EAP), constituted from the research 
team, consisting of four pharmacists, three of whom had signifi-
cant previous care home experience, a medical public health con-
sultant, two geriatricians, a senior research nurse, a senior care home 
manager and two patient and public involvement representatives, 
oversaw the process. Recognising a priori that participating PIPs 
were likely to vary in their care home knowledge and experience, it 
was agreed that the training programme should include a Personal 
Development Framework to structure learning and enable the PIP to 
address any knowledge or skill gaps. The mode of assessment was 
to be determined. Competencies identified as necessary, but already 
demonstrated to achieve prescribing status,[19] were excluded.
Phase 1: Initial stakeholder engagement
As part of the main programme of CHIPPS work, focus groups and 
interviews were undertaken primarily to define the PIP service speci-
fication while operating within the care homes.[16] The topic guides 
included a question regarding pharmacist-training needs for the con-
tent of the PIP training programme. These elements were extracted 
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them into codified, practical or cultural knowledge, or for consider-
ation within the training programme design.
The elements from the content analysis were combined with 
elements from the previously reported literature review,[18] indi-
vidually numbered and categorised into: an expected behaviour 
(practical and cultural knowledge-based); a described activity to be 
undertaken in preparation for the role (to address identified cultural 
and practical knowledge needs. Expected behaviours were then com-
bined by N.N. and D.J.W.  into competencies, and these were then 
ordered into domains within the Personal Development Framework 
(Supplementary Appendix S1).
The first draft of the training programme with the proposed 
Personal Development Framework was presented to the EAP to 
review and amend to create Draft 2.  This was then used within 
training-specific focus groups and interviews as described below.
Phase 2: Uni-professional focus groups and 
interviews
Focus groups with different healthcare professional groups were or-
ganised and located across four sites as follows:
• Primary care pharmacists (Leeds)
• General practitioners (Aberdeen)
• Community pharmacists (Belfast)
• Care home staff (Norwich)
Additionally, within each site, an appropriate healthcare pro-
fessional (local adviser) with significant local care home experience 
regarding medicines management was identified and recruited for 
participation in an interview to enable identification of local envir-
onmental and contextual factors (local cultural knowledge) which 
might require consideration.
All focus group and interview participants were identified pur-
posively by local principal investigators. Before each focus group 
and interview, Draft 2 of the training programme including the 
Personal Development Framework was provided to participants. 
Focus groups and interviews were chaired or led by N.N. and mod-
erated by D.J.W. The topic guide consisted of the following:
• Initial views on the draft training programme
• Therapeutic and clinical areas to be included
• Care home-specific processes which pharmacists would need to 
be aware of
• Knowledge required to be effective
• Interprofessional-related knowledge
• Any advice participants could provide relating to preparing 
pharmacists
Focus groups/interviews were recorded digitally, transcribed ver-
batim and content analysed by D.J.W. and validated by N.N.
Where possible, consensus on any amendments and enhance-
ments to the training programme and framework was identified, 
with a final decision sought from the EAP if needed.
Phase 3: Expert consensus
A consensus day was held at each study site primarily to develop 
the CHIPPS service specification but also to obtain feedback on 
the draft training programme. Participants included a primary care 
pharmacist (preferably a PIP), general practitioner (GP), community 
pharmacist, care home manager, care home staff member, resident 
and/or relative, plus any other relevant local stakeholder, for ex-
ample, local primary care organisation Medicines Management 
Lead. The panel was asked to provide feedback on:
• Their initial views on the draft training programme
• Whether all competencies should be assessed or just those which 
had been agreed with the mentor as requiring development
• The mode of assessment to be used
• Points of dissonance identified within the stakeholder focus 
groups and interviews
Detailed notes were taken from the consensus panels and used 
by N.N. and D.J.W. to create a final draft training programme for 
feasibility testing.
Phase 4: Feasibility testing
Four PIPs, GPs and care homes, each with 10 consented residents, 
were recruited, through local networks, to the feasibility phase of 
the study.[20] The training programme was implemented before the 
PIPs providing the service over a 3-month period. At the end of the 
feasibility phase, a focus group with the PIPs was convened to obtain 
feedback on the effectiveness and acceptability of the training pro-
gramme. The topic guide consisted of questions regarding:
• Personal development planning and support process
• Personal Development Framework (Personal Development 
Framework)
• Assessment process
• Impact of the training
• Elements which worked well and those which worked less well
The focus group was recorded, transcribed verbatim and content 
analysed to refine the draft training programme for use within the 
main trial.
Results
Phase 1: Initial stakeholder engagement
Thirteen interviews and 13 focus groups with 72 participants were 
undertaken.[16] Figure 1 shows the different types of knowledge iden-
tified as important for inclusion in the training.
The following training activities, in addition to face-to-face 
training, were included to develop identified cultural knowledge re-
quirements, to support relationship development and enable identifi-
cation of care home staff training needs:
• Shadowing care staff and observing medicines’ administration
• Shadowing a GP and agreeing responsibilities and boundaries
• Time within care home and medical practice to learn how to use 
Information Technology systems
The practical knowledge identified as important was how 
to provide pharmaceutical care for older people with frailty. 
Supplementary Appendix S1 provides a copy of the first draft of the 
training programme.
The EAP identified the need for ‘context’ to be included as a do-
main within the Personal Development Framework and to change 
the ‘chronic disease management’ domain to ‘managing complexity 
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Phase 2: Uni-professional expert focus groups and 
interviews
Six primary care pharmacists, six GPs, five community pharmacists, 
six care home staff participated in four focus groups and local ad-
visers (three pharmacists and one doctor) participated in interviews. 
Recommended changes to the overall training programme and 
Personal Development Framework are provided in Box 1. A copy 
of the revised training programme resulting from this is provided in 
Supplementary Appendix S3.
Phase 3: Expert consensus
Four consensus panels were held between 2 February 2016 and 2 
December 2016 with 53 attendees (Aberdeen, n = 12; Yorkshire and 
Humber, n = 12; Norwich, n = 15; Belfast, n = 14). Across the con-
sensus panels, there were 13 GPs, 3 care home managers, 7 care 
home staff, 4 care home resident/relatives, 13 primary care phar-
macists, 10 community pharmacists, 1 individual responsible for 
medicines standards in care homes, 1 senior medicines management 
technician and 1 GP federation chair. Box 2 provides a summary of 
what was agreed within Phase 3. The underpinning knowledge iden-
tified as being required by PIPs is provided within Figure 2.
Draft 4 of the training programme, which was used in Phase 4, 
is provided in Figure 3.
Phase 4: Feasibility testing
The four PIPs were all female, all had previously worked as pharma-
cists within the care home environment and two of them already had 
a working relationship within the recruited medical practice. None 
had worked previously with the recruited care homes.
The training was viewed positively by all four PIPs, reported to be 
motivational and enhanced their confidence to operate within the role.
It’s had a really positive impact, the fact that it has made you 
more motivated and certainly more clued in and more con-
fident in going in and making changes to a patient’s medica-
tions. (PIP 4)
The mentor was seen as a valuable support as well as an ex-
perienced advisor for the PIPs. It was thought that a face-to-face 
meeting with the independent evaluator would have been preferable 
but overall, the combination of mentor and GP assessor was con-
sidered helpful, and it generated ideas and confidence.
The process of working on the personal development plans was 
reported as being effective in consolidating existing knowledge as 
well as revealing knowledge gaps. It was considered to be valid, rele-
vant, necessary and aided reflection. However, the process of col-
lecting evidence against the Personal Development Framework could 
have been less time-consuming if there had been better guidance on 
expectations regarding this from the outset.
Codified Knowledge
Frailty
Harmful drugs in older people
Capacity and how to support residents without it
End of life care
Role and boundaries of self and others
Management of geriatric condions
Medicines regulaons in care homes
Importance of involving residents and relaves in decision making
Praccal knowledge
Know limitaons and to work within them
How to integrate into team
Good communicaon with team, with residents and relaves
Need for use of IT systems in home and medical pracce
Cultural knowledge
Develop relaonships with everyone involved in team
How medical pracce servicing the home operates
Care home culture with respect to medicines
Impact of medicines within the care home
Medicines ordering and supply processes to enable effecve access to medicines
Training delivery design
To support integraon into team
Ensure includes effecve communicaon of PIP role to home and wider team members
Mentoring and/or shadowing as part of training. Doctors and care workers
PIPs to communicate to staff the importance of managing medicines effecvely
PIPs to understand and support good medicines administraon pracses 
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While all elements were viewed positively, the elements of the 
face-to-face training that were perceived as particularly effective 
were the case studies surrounding the management of complexity, 
legal issues and covert administration and the session on the man-
agement of psychotropic medication.
The most useful ones were certainly the case studies that 
were discussed with the geriatrician, so that was really good 
to work things through and discuss things as well, because 
I guess you just learn more from real life cases and commonly 
used drugs that you would see in elderly patients, particularly 
in relation to things like dementia. And also the antipsychotic 
training was excellent as well. The standard of training was 
all very good but those are ones that sort of like really stand 
out above. (PIP 4)
Following Phase 4, no major changes were made to the training 
programme.
Discussion
This systematic and iterative development and testing of a training 
programme for pharmacists with prescribing rights to provide 
pharmaceutical care for care home residents resulted in a product 
that was relevant and equipped participants for their care home role. 
The model of using a Personal Development Framework, mentor 
and assessor, supported with an underpinning knowledge pack and 
specific face-to-face training, was shown to be acceptable and prac-
tical. Implementation resulted in PIPs who were motivated to under-
take the role and confident to do so.
The process of data collection was robust, encompassing the full 
range of stakeholders. Development of the training programme was 
systematic, iterative and guided by an EAP. Although the literature 
review identified much of the codified and practical knowledge re-
quired by the PIPs, it was the qualitative data collection undertaken 
here, which identified the cultural knowledge requirements.
The training programme was only tested on four PIPs who could 
be seen as early adopters who may not fully represent the range of 
abilities and experiences of other pharmacist prescribers wishing 
to develop competence within care homes. Consequently, without 
implementation and testing in a wider population, its practicability 
and acceptability need to be further established. We used the same 
mentor and medical assessor for all four PIPs and again, if the role 
were to expand, training for the mentors would be required to en-
sure consistency with respect to both support and assessment.
The feasibility stage lasted for only 3 months and its appropriate-
ness for delivery long term is also unknown. Testing in over 20 PIPs 
undertaking this role over 6 months will occur within the main trial.[21]
A key area of agreement through our findings was the recognised 
need for the PIP to develop relationships with the care home staff, 
medical practice and community pharmacist. Activities to be under-
taken when spending time with each were identified to ensure that 
the PIPs developed an understanding of local cultures, communica-
tion preferences and the expected boundaries for their prescribing 
practice. Consequently, training time was allocated for this purpose 
within the training programme. Interestingly, the four PIPs at the 
feasibility stage did not refer explicitly to time spent undertaking 
preparatory activities and we did not formally monitor adherence 
to this requirement. We therefore have limited insight into its effect-
iveness or appropriateness. As ‘early adopters’, they may represent 
more confident and outgoing individuals for whom relationship de-
velopment occurs more readily. Within the planned definitive trial, 
there will be over 20 PIPs and at this stage, we will need to monitor 
and evaluate the effectiveness of providing time to develop relation-
ships, integrate into local teams and understand local cultures.
The model of using Personal Development Frameworks to en-
able individuals to identify their learning needs is commonplace 
within the healthcare professional literature.[22–24] Mentors are seen 
as necessary as they can support the learning need identification 
process, identify experiential opportunities to develop the required 
knowledge and help with collation of evidence.[25, 26] Mentors are 
also frequently used to both support and sign-off trainees as compe-
tent within their role,[27] however, the appropriateness of this model 
has been questioned due to the mentor developing a relationship 
with the mentee and recognition that this may adversely affect their 
judgement.[28] Consequently, we used an independent assessor in 
addition to the mentor.
Box 1. Phase 2: Recommended changes to the training programme
Overall training programme
 • PIPs identify support available for the home from other health-
care professionals and how to refer residents to them
 • Include ‘identification of red flags’, ‘management of antidepres-
sants’ and ‘anticholinergic burden’ in face-to-face training
 • PIPs visit a care home with partner GP to undertake 
medication reviews together to identify expectations and 
boundaries
 • Include an induction period to meet: community pharmacist, 
community matron, Care Quality Commission lead, consultant 
geriatrician, district nurse, local safety expert, care home phar-
macists, as appropriate to local setting
Personal Development Framework
Include the following competency:
 • Responds appropriately to medicines-related errors and critical 
incidents
Include the following behaviours (those things which underpin 
the related competencies):
 • Ensures that resident nutritional needs are regularly reviewed 
and related prescribing is in line with local policy and guidance
 • Ensures patient rights under Mental Capacity Act, for example, 
covert administration, right of refusal
 • Supports effective transfer of medicines-related information 
when residents are hospitalised
 • Ensures that medicines-related information transferred from 
hospital to the care home is accurate and complete
 • Ensures that prescribing and monitoring practices relating to 
high-risk therapy, for example, anti-platelet and anticoagulant 
therapy, are appropriate
 • Reviews and rationalises therapy in light of risk and benefits in a 
complex older person
Reword the following:
 • The focus regarding pain management to remove the need for 
PIPs to undertake formal pain assessment for each resident
 • Change ‘palliative care’ to ‘terminal care’ in the Framework as 
the latter better describes the point at which the PIPs would not 
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Figure 2 Underpinning knowledge required for safe practice within care homes.
Box 2. Phase 3: Agreed changes to the training programme
Face-to-face training
 • Delivered by a geriatrician and experienced pharmacist
 • Use case studies regarding
◦ complexity in older person’s medicines in care homes
◦ common legal and ethical issues
◦ assessment of capacity
◦ use of care plans and record-keeping
 • Underpinning knowledge pack
 • Large number of areas of knowledge identified as required to 
underpin competency resulted in the development of a know-
ledge pack consisting of links to current papers, websites, reports 
and guidelines.
Preparation for role
 • Significant amount of time to be allocated to the development 
of relationships and that training care staff was an important 
element within this.
Personal Development Framework
 • Include ‘Trains others’ under communication skills domain
 • ‘Delivers effective small group teaching sessions’ and ‘Provides 
feedback on performance sensitively and constructively’ as be-
haviours to underpin ‘Trains others’.
 • Wound management not to be included as a competency.
 • Medicines’ discontinuation included within the ‘Safe and ef-
fective medicines’ alteration’ competency.
Development process
 • PIPs to use the Personal Development Framework initially for 
self-assessment with support from a mentor (senior pharmacist 
with care home expertise)
 • Mentor support to continue through the development process
Assessment/accreditation process
 • Assessment only of those competencies identified as ‘requiring 
development’ within personal development plan
 • Oral viva with both mentor and independent evaluator 
(medical practitioner with an expertise in care homes) 
sign-off.
 • PIP to be graded as either ‘competent’, ‘safe but still requiring 
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Formal assessment of competence is unusual as PIPs in the UK 
are allowed to self-certify competence. The requirement for inde-
pendent external assessment resulted from medical practitioner 
concerns regarding the safety of this model. With no safety net for 
the pharmacist who is now making final prescribing decisions for a 
population who are likely to be frail and have complex conditions, it 
was believed necessary to attach this extra layer of quality assurance. 
It is also appropriate to assess for competency in a trial where inter-
ventions to enhance fidelity are required[29] and assessment can be 
used to ensure that those who deliver the main trial intervention do 
operate at the expected level. Within the four PIPs in the feasibility 
stage, the inclusion of assessment was seen as positive and effective 
at enhancing individual confidence. Whether it would be included 
in any future commissioned service would need to be decided, but 
evidence suggests that while it is likely to add to expense, additional 
benefits would be derived from this.
Due to cost and recognition that PIPs will all have different 
learning needs, face-to-face training was limited to those topics 
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deemed to be most important for patient safety and PIP effectiveness. 
Understanding of managing complexity and frailty was seen as core 
knowledge for pharmacists in care homes and consequently, we chose 
to deliver training on this element via case studies with a geriatri-
cian and a pharmacist with expertise in managing medicines in older 
people leading the session jointly. This element of the training was 
appreciated by the PIPs and was seen to enhance their confidence. 
The experience of Covid-19 may promote training to be undertaken 
virtually, rather than face-to-face, thereby reducing travel and accom-
modation costs experienced within this programme of research. The 
identification of knowledge required by PIPs to undertake their role 
and underpin their competencies created some concern for the team 
anticipating the time required to develop the materials. However, rec-
ognition that such materials were already available and in the public 
domain enabled us to rapidly produce a document consisting of web 
links to relevant guidelines, pages and documents. A model of this 
nature is also relatively easy to regularly update.
The overall model we have developed here, is very similar to 
that which was subsequently used to underpin a concurrent national 
initiative to integrate pharmacists into care homes for medicines 
optimisation purposes. Face-to-face training, support materials, 
competency framework and mentoring were similarly provided.[30] 
Consequently, demonstrating the potential feasibility of our training 
programme for preparing pharmacists to undertake the central 
medicines management role within care homes.
Although pharmacist prescribing is still limited to a minority of 
countries, the opportunity for direct transferability of these results 
is small. However, with the training programme underpinned by ex-
tensive international literature regarding pharmacist activities within 
care homes, we believe that it could transfer across countries and to 
pharmacists without prescribing rights. With all frameworks of this 
nature, they are, however, more likely to be effective if adapted to 
the context and target audience. Furthermore, to enhance ownership 
of, and engagement with, any training programme of this nature it is 
always best to involve the users in its design.
Conclusion
This novel and extensive approach has produced a comprehensive 
training programme to enable PIPs to provide pharmaceutical care 
within care homes. Comprehensive engagement with key stake-
holders within the process should engender greater buy-in when the 
intervention is delivered.
The feasibility of the training programme was demonstrated 
with PIPs feeling confident and competent to perform their role. 
Larger scale testing of our package is now required before broader 
dissemination.
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